Harpagide

CAS# 6926-08-5

Harpagide

2D Structure

Catalog No. BCN4996----Order now to get a substantial discount!

Product Name & Size Price Stock
Harpagide: 5mg $35 In Stock
Harpagide: 10mg Please Inquire In Stock
Harpagide: 20mg Please Inquire Please Inquire
Harpagide: 50mg Please Inquire Please Inquire
Harpagide: 100mg Please Inquire Please Inquire
Harpagide: 200mg Please Inquire Please Inquire
Harpagide: 500mg Please Inquire Please Inquire
Harpagide: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Harpagide

3D structure

Package In Stock

Harpagide

Number of papers citing our products

Chemical Properties of Harpagide

Cas No. 6926-08-5 SDF Download SDF
PubChem ID 93045 Appearance Colorless-light yellow powder
Formula C15H24O10 M.Wt 364.35
Type of Compound Iridoids Storage Desiccate at -20°C
Solubility Soluble in methanol and water
Chemical Name (1S,4aS,5R,7S,7aR)-7-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,5,6,7a-tetrahydrocyclopenta[c]pyran-4a,5,7-triol
SMILES CC1(CC(C2(C1C(OC=C2)OC3C(C(C(C(O3)CO)O)O)O)O)O)O
Standard InChIKey XUWSHXDEJOOIND-YYDKPPGPSA-N
Standard InChI InChI=1S/C15H24O10/c1-14(21)4-7(17)15(22)2-3-23-13(11(14)15)25-12-10(20)9(19)8(18)6(5-16)24-12/h2-3,6-13,16-22H,4-5H2,1H3/t6-,7-,8-,9+,10-,11-,12+,13+,14+,15-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Harpagide

1 Harpagophytum sp. 2 Scrophularia sp. 3 Teucrium sp. 4 Verbascum sp.

Biological Activity of Harpagide

DescriptionHarpagide has neuroprotective effect, it can obviously protect acute cerebral ischemia in mice,its therapeutical effects are approached to protecting the activity of brain mitochondria and decreasing protein expression level of caspase-3; harpagide also has a potential for prevention of bone loss in ovariectomized (OVX) mice by regulating the stimulation of osteoblast differentiation and the suppression of osteoclast formation. Harpagide may have anti-inflammatory efficacy.
TargetsTNF-α | NO | COX | Caspase | Calcium Channel | ATPase
In vitro

Effects of β-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro.[Pubmed: 21775152 ]

Bioorg Med Chem. 2011 Aug 15;19(16):4882-6.

Harpagide (1) and harpagoside (2) are two iridoid glycosides existing in many medicinal plants. Although they are believed to be the main bioactive compounds related to the anti-inflammatory efficacy of these plants, the mechanisms of their anti-inflammatory activities remain unclear.
METHODS AND RESULTS:
The results of our present study showed that 1 and 2 had no effects on inhibitions of cyclooxygenase (COX)-1/2 enzyme activity, tumor necrosis factor-α (TNF-α) release, and nitric oxide (NO) production in vitro. However, the hydrolyzed products of 1 and 2 with β-glucosidase treatment showed a significant inhibitory effect on COX-2 activity at 2.5-100 μM in a concentration-dependent manner. Our further study revealed that the hydrolyzed 2 product was structurally the same as the hydrolyzed 1 product (H-Harpagide (3)). The structure of 3 was 2-(formylmethyl)-2,3,5-trihydroxy-5-methylcyclopentane carbaldehyde, with a backbone similar to prostaglandins and COX-2 inhibitors such as celecoxib. All of them have a pentatomic ring with two adjacent side chains.
CONCLUSIONS:
The result of molecular modeling and docking study showed that 3 could bind to the COX-2 active domain well through hydrophobic and hydrogen-bonding interactions, whereas 1 and 2 could not, implying that the hydrolysis of the glycosidic bond of 1 and 2 is a pre-requisite step for their COX-2 inhibitory activity.

In vivo

Neuro-protective effect of harpagide on acute cerebral ischemic injury in mice and its mechanism involving mitochondria.[Reference: WebLink]

Journal of Chinese Pharmaceutical Sciences, 2015, 50(12):1026-31.

To observe the neuro-protective effects of Harpagide on acute cerebral ischemic injury in mice and its mechanism involving mitochondria.
METHODS AND RESULTS:
Acute cerebral ischemia were achieved by operation of MCAO in the left brain, random allocation was taken to divide ICR mice into sham group, model group, nimodipine group and Harpagide (5,10,15 mg·kg-1) groups. Mice were intraperitoneal injected Harpagide immediately after surgeiy. Nerve function score, content of brain water, brain index and the common changes of brain pathological structure in HE staining were measured: Ability of mitochondria Ca2+-Mg2+-AT-Pase and protein expression level of caspase-3 in the MCAO mice' brains was determined: Ultrastructure change of mitochondria under the TEM was observed. Compared with model group, the Harpagide groups could decreased the nerve function score, the content of brain water, brain index and the volume of ischemia in mice with different degrees in MCAO mice (P<0.05, P<0.01). 10 mg·kg-1 of Harpagide could increased the activity of Ca2+-Mg2+-ATPase obviously (P<0.01): And significantly decreased the protein expression level of caspase-3 (P<0.01): Harpagide groups could protect the pathogeny structure and the ultrastructure of mitochondria with different degrees in MCAO mice, decrease edema of mitochondria obviously.
CONCLUSIONS:
Harpagide could obviously protect acute cerebral ischemia in mice, its therapeutical effects are approached to protecting the activity of brain mitochondria and decreasing protein expression level of caspase-3.

Protocol of Harpagide

Cell Research

Protective effects of Harpagide and Harpagoside on human vascular endothelial cells injury induced by hydrogen peroxide.[Reference: WebLink]

Medical Research & Education, 2009, 26(2):11-2.

To investigate protective effects of Harpagide and Harpagoside on human vascular endothelial cells(HUVECS) injury induced by hydrogen peroxide(H2O2).
METHODS AND RESULTS:
The well grown 3-5 generations HUVECS were cultured for study and divided into control group,H2O2 group,Harpagide group and harpagoside group.The morphologic of HUVECS were observed under light microscope and HUVECS activities were determined by the methyl thiazolyl tetrazolium(MTT)assay.The contents of lactate dehydrogenises(LDH) and malonadehyde(MDA) in the supernatant of HUVECS were determined by the spectra photometric assay. Harpagide and Harpagoside made morphologic changes of HUVECS induced by H2O2 tend to normal,increased the activities of HUVECS and lessened the injury of cell membrane,decreased the contents of MDA and LDH.
CONCLUSIONS:
Harpagide and harpagoside could inhibit the injury of HUVECS induced by H2O2.

Animal Research

Anti-osteoporotic activity of harpagide by regulation of bone formation in osteoblast cell culture and ovariectomy-induced bone loss mouse models.[Pubmed: 26712566 ]

J Ethnopharmacol. 2016 Feb 17;179:66-75.

Harpagide, an iridoid glucoside, is a constituent of the root of Harpagophytum procumbens var. sublobatum (Engl.) Stapf, Devil's claw which has been used in patients with osteoarthritis (OA). In the present study, we investigated the anti-osteoporotic potential of Harpagide and its underlying mechanism of action in in vitro cell culture and in vivo bone loss animal models. Harpagide was obtained from the alkalic hydrolysis of harpagoside, a major constituent of H. procumbens var. sublobatum Analysis of biomarkers for bone formation in osteoblastic MC3T3-E1 cells and bone resorption in osteoclast cells derived from mouse bone marrow cells was performed to evaluate the mechanism of action.
METHODS AND RESULTS:
The protective activity of Harpagide against bone loss was also evaluated in ovariectomized (OVX) mouse model. Harpagide improved bone properties by stimulating the process of differentiation and maturation of osteoblast cells and suppressing the process of RANKL-induced differentiation of osteoclast cells. In OVX-induced bone loss mouse model, oral administration of Harpagide significantly improved recovery of bone mineral density, trabecular bone volume, and trabecular number in the femur. Harpagide also prevented increase of trabecular separation and structure model index induced by OVX. Harpagide effectively inhibited the serum levels of biochemical markers of bone loss, including alkaline phosphatase, osteocalcin, C-terminal telopeptide, and tartrate-resistant acid phosphatase.
CONCLUSIONS:
Taken together, the present study demonstrates that Harpagide has a potential for prevention of bone loss in OVX mice by regulating the stimulation of osteoblast differentiation and the suppression of osteoclast formation. Therefore, these findings suggest that Harpagide might serve as a bioactive compound derived from H. procumbens var. sublobatum for improvement of age-dependent bone destruction disease.

Harpagide Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Harpagide Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Harpagide

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.7446 mL 13.7231 mL 27.4461 mL 54.8923 mL 68.6153 mL
5 mM 0.5489 mL 2.7446 mL 5.4892 mL 10.9785 mL 13.7231 mL
10 mM 0.2745 mL 1.3723 mL 2.7446 mL 5.4892 mL 6.8615 mL
50 mM 0.0549 mL 0.2745 mL 0.5489 mL 1.0978 mL 1.3723 mL
100 mM 0.0274 mL 0.1372 mL 0.2745 mL 0.5489 mL 0.6862 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Harpagide

Anti-osteoporotic activity of harpagide by regulation of bone formation in osteoblast cell culture and ovariectomy-induced bone loss mouse models.[Pubmed:26712566]

J Ethnopharmacol. 2016 Feb 17;179:66-75.

ETHNOPHARMACOLOGICAL RELEVANCE: Harpagide, an iridoid glucoside, is a constituent of the root of Harpagophytum procumbens var. sublobatum (Engl.) Stapf, Devil's claw which has been used in patients with osteoarthritis (OA). In the present study, we investigated the anti-osteoporotic potential of Harpagide and its underlying mechanism of action in in vitro cell culture and in vivo bone loss animal models. MATERIAL AND METHODS: Harpagide was obtained from the alkalic hydrolysis of harpagoside, a major constituent of H. procumbens var. sublobatum Analysis of biomarkers for bone formation in osteoblastic MC3T3-E1 cells and bone resorption in osteoclast cells derived from mouse bone marrow cells was performed to evaluate the mechanism of action. The protective activity of Harpagide against bone loss was also evaluated in ovariectomized (OVX) mouse model. RESULTS: Harpagide improved bone properties by stimulating the process of differentiation and maturation of osteoblast cells and suppressing the process of RANKL-induced differentiation of osteoclast cells. In OVX-induced bone loss mouse model, oral administration of Harpagide significantly improved recovery of bone mineral density, trabecular bone volume, and trabecular number in the femur. Harpagide also prevented increase of trabecular separation and structure model index induced by OVX. Harpagide effectively inhibited the serum levels of biochemical markers of bone loss, including alkaline phosphatase, osteocalcin, C-terminal telopeptide, and tartrate-resistant acid phosphatase. CONCLUSION: Taken together, the present study demonstrates that Harpagide has a potential for prevention of bone loss in OVX mice by regulating the stimulation of osteoblast differentiation and the suppression of osteoclast formation. Therefore, these findings suggest that Harpagide might serve as a bioactive compound derived from H. procumbens var. sublobatum for improvement of age-dependent bone destruction disease.

Effects of beta-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro.[Pubmed:21775152]

Bioorg Med Chem. 2011 Aug 15;19(16):4882-6.

Harpagide (1) and harpagoside (2) are two iridoid glycosides existing in many medicinal plants. Although they are believed to be the main bioactive compounds related to the anti-inflammatory efficacy of these plants, the mechanisms of their anti-inflammatory activities remain unclear. The results of our present study showed that 1 and 2 had no effects on inhibitions of cyclooxygenase (COX)-1/2 enzyme activity, tumor necrosis factor-alpha (TNF-alpha) release, and nitric oxide (NO) production in vitro. However, the hydrolyzed products of 1 and 2 with beta-glucosidase treatment showed a significant inhibitory effect on COX-2 activity at 2.5-100 muM in a concentration-dependent manner. Our further study revealed that the hydrolyzed 2 product was structurally the same as the hydrolyzed 1 product (H-Harpagide (3)). The structure of 3 was 2-(formylmethyl)-2,3,5-trihydroxy-5-methylcyclopentane carbaldehyde, with a backbone similar to prostaglandins and COX-2 inhibitors such as celecoxib. All of them have a pentatomic ring with two adjacent side chains. The result of molecular modeling and docking study showed that 3 could bind to the COX-2 active domain well through hydrophobic and hydrogen-bonding interactions, whereas 1 and 2 could not, implying that the hydrolysis of the glycosidic bond of 1 and 2 is a pre-requisite step for their COX-2 inhibitory activity.

Description

Harpagide is a class of iridoid glycoside isolated from Scrophularia cryptophila and has antiparasitic activity, which exhibits good in vitro trypanocidal activities against African trypanosomes (T.b. rhodesiense) with an IC50 of 21 μg/mL. Harpagide exerts significant antileishmanial activity against L. donovani with an IC50 value of 2.0 μg/mL. Harpagide also possess significant anti-inflammatory activities.

Keywords:

Harpagide,6926-08-5,Natural Products, buy Harpagide , Harpagide supplier , purchase Harpagide , Harpagide cost , Harpagide manufacturer , order Harpagide , high purity Harpagide

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: